Clearmind Medicine Inc.CMND
Price (close)
$0.80
Market cap
$2.7M
P/E
—
Revenue (FY)
—
Net income
-$3.9M
Dividend yield
—
1-year total return
-99.8%
Net margin
—
Revenue growth
—
Debt / equity
—
What Clearmind Medicine Inc. does.
currently engaged in phase I/IIa clinical trials of novel psychedelic medicines to solve widespread, yet under-served, health problems.
Our goal is to develop and provide new type of treatments for mental health disorders, including AUD, binge drinking and eating disorders,
where there is significant unmet need and lack of innovation. We see neuroplastogens based therapies, which previously may have been
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net income | — | -$2.7M | -$6.9M | -$8.6M | -$5.3M | -$3.9M |
| Free cash flow | — | -$2.1M | -$3.7M | — | — | — |
More on CMND.
- Clearmind Medicine Inc. summary
- Clearmind Medicine Inc. financial statements
- Clearmind Medicine Inc. key metrics
- Clearmind Medicine Inc. health scores and style box
- Clearmind Medicine Inc. earnings
- Clearmind Medicine Inc. dividends
- Clearmind Medicine Inc. valuation
- Clearmind Medicine Inc. ownership and insiders
- Clearmind Medicine Inc. peers
Figures from Clearmind Medicine Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.